ReviewFuture oncology (London, England)2016
The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.
Review in Future oncology (London, England), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03741829 (TS Overexpression in SCLC), which is not on this map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TS Overexpression in SCLC: Mechanism and Therapeutic Targeting
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Colorectal Cancer: Differential Gene Expression and In Vitro Response to 5-Fluorouracil, Novel Fluoropyrimidine F10, and Potential Synergy with Lupeol.International journal of molecular sciences · 2025Article
- The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress.Cancer biology & therapy · 2024Article
- Oligonucleotides Carrying Nucleoside Antimetabolites as Potential Prodrugs.Current medicinal chemistry · 2023Review
- Evaluation of Floxuridine Oligonucleotide Conjugates Carrying Potential Enhancers of Cellular Uptake.International journal of molecular sciences · 2021Article
- AraC-FdUMP[10] Is a Next-Generation Fluoropyrimidine with Potent Antitumor Activity in PDAC and Synergy withMolecular cancer research : MCR · 2021Article
- Parallel G-quadruplex Structures Increase Cellular Uptake and Cytotoxicity of 5-Fluoro-2'-deoxyuridine Oligomers in 5-Fluorouracil Resistant Cells.Molecules (Basel, Switzerland) · 2021Article
- Co-delivery of 5-fluorodeoxyuridine and doxorubicin via gold nanoparticle equipped with affibody-DNA hybrid strands for targeted synergistic chemotherapy of HER2 overexpressing breast cancer.Scientific reports · 2020Article
- Chemistry of Fluorinated Pyrimidines in the Era of Personalized Medicine.Molecules (Basel, Switzerland) · 2020Review
- Fluoropyrimidine Modulation of the Anti-Tumor Immune Response-Prospects for Improved Colorectal Cancer Treatment.Cancers · 2020Review
- Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy.Cancers · 2020Review
- Article
- Development of a Colorectal Cancer 3D Micro-tumor Construct Platform From Cell Lines and Patient Tumor Biospecimens for Standard-of-Care and Experimental Drug Screening.Annals of biomedical engineering · 2020Article
- Enhancing Antitumor Efficacy of Nucleoside Analog 5-Fluorodeoxyuridine on HER2-Overexpressing Breast Cancer by Affibody-Engineered DNA Nanoparticle.International journal of nanomedicine · 2020Article
- Nucleic Acids as a Nature-Inspired Scaffold for Macromolecular Prodrugs of Nucleoside Analogues.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs.Cancer drug resistance (Alhambra, Calif.) · 2019Article
- Overview of DNA Self-Assembling: Progresses in Biomedical Applications.Pharmaceutics · 2018Review
- Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition.Neoplasia (New York, N.Y.) · 2018Article
- Floxuridine Homomeric Oligonucleotides "Hitchhike" with Albumin In Situ for Cancer Chemotherapy.Angewandte Chemie (International ed. in English) · 2018Article
- Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations.Cancer drug resistance (Alhambra, Calif.) · 2018Article
- All-atom MD indicates ion-dependent behavior of therapeutic DNA polymer.Physical chemistry chemical physics : PCCP · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
F10 is a novel polymeric fluoropyrimidine drug candidate with strong anticancer activity in multiple preclinical models. F10 has strong potential for impacting cancer treatment because it displays high cytotoxicity toward proliferating malignant cells with minimal systemic toxicities thus providing an improved therapeutic window relative to traditional fluoropyrimidine drugs, such as 5-fluorouracil. F10 has a unique mechanism that involves dual targeting of thymidylate synthase and Top1. In this review, the authors provide an overview of the studies that revealed the novel aspects of F10's cytotoxic mechanism and summarize results obtained in preclinical models of acute myeloid leukemia, acute lymphocytic leukemia, glioblastoma and prostate cancer that demonstrate the strong potential of F10 to improve treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.